ClinicalTrials.gg
RecruitingNCT06005103Updated Aug 26, 2025

A Randomized Clinical Trial Comparing Active Versus Sham T-PEMF Headband Treatment for Depression

An interventional study of Treatment with MoodHeadBand (T-PEMF treatment) and Inactive treatment with MoodHeadBand (Placebo) in Moderate Depression, Severe Depressive Episode Without Psychotic Symptoms and Recurrent Depressive Disorder, Current Episode Moderate, sponsored by Mental Health Centre Copenhagen, Bispebjerg and Frederiksberg Hospital. Recruiting at 1 site in Denmark. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-08-26.

Sponsored by Mental Health Centre Copenhagen, Bispebjerg and Frederiksberg Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2024; still recruiting 2 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
117
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 27 studies in Depressive Disorder with a site in Denmark — 3 open to participants now, 4 under way, none of them phase 3. Depressive Disorder · Denmark.

Planned enrollment
8th of 23
117 · median 64
Started
2024
with 2 others
No phase
19 of 27
2 open now
Registered
22nd of 27
by date

Among the 27 studies in Depressive Disorder with a site in Denmark, this one is the 8th largest by planned enrollment of the 23 interventional ones that give a count, is one of 3 that started in 2024, is one of 19 with no phase, and was the 22nd registered.

Depressive Disorder

857 studies on the registry are indexed under Depressive Disorder; 160 are open to participants now.

Browse Depressive Disorder studies →

Open to participants now

3 of the 27 studies in Depressive Disorder with a site in Denmark are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →

Who these studies take

Of the 116 Depressive Disorder studies recruiting now, 44 (38%) set no upper age limit and 66 (57%) stop at 75 or younger; 24 take children under 18; 25 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies in Depressive Disorder with a site in Denmark, or all of them as a file.
02

Study summary

An 8-week, two-armed, randomized-controlled trial that examines the antidepressant effect of treatment with transcranial pulsed electromagnetic fields (T-PEMF) in patients diagnosed with moderate to severe depression using using a new device, the MoodHeadBand (MHB).

The participants will use an active or placebo MHB for 30 minutes daily for 8 weeks.

Additionally, the following research questions will be answered:

1. If there is a positive effect on the patients' emotional and non-emotional cognition after 8 weeks of active treatment compared to the sham group and if possible early changes in the emotional cognition can predict the treatment response after 8 weeks of treatment.

1. If the T-PEMF treatment provides improvement in restorative sleep after 8 weeks of treatment

Read the detailed description

The purpose of this study is to clarify whether daily treatment over eight weeks with weak pulsating electromagnetic fields (T-PEMF) can achieve a safe effect on depression compared to the same treatment with a placebo T-PEMF. The study will furthermore explore possible effects on cognition and the hypothesized sleep-ameliorating effect of T-PEMF. Previous Danish studies have shown a significant antidepressant effect of other T-PEMF devices in the treatment of patients with depression.

The study is designed as a blinded, randomized study where active treatment is compared with inactive (placebo) treatment. At the same time, possible side effects in the use of the headband (MoodHeadBand, MHB) are investigated.

The project was initiated June 2024. Patients consecutively referred are asked after an initial interview whether they wish to participate in the study. If they give informed consent to this, they will be randomized to active or placebo treatment. The treatment itself takes place at home, 30 minutes once a day, for 8 weeks. "Treatment as usual" takes place in parallel to the study treatment, and consists of psychotherapy in a group or individually and antidepressive medications. Follow-ups will be conducted weekly either as visits at the clinic, via videocall or as telephone calls. The participants will receive weekly surveys they are encouraged to fill out prior to the weekly follow-ups. The severity of the depression, including its symptomatology will be examined weekly during the study, the cognitive test-battery is applied at baseline, week 1 and at the final visit, the patients sleep-pattern and possible disturbances are examined via the weekly surverys.

No significant side effects have been registered when using the same type of electromagnetic field treatment in the previous Danish studies. It has also been shown that it is possible to carry out the treatment at home without significant problems.

03

Conditions studied

  • Moderate Depression
  • Severe Depressive Episode Without Psychotic Symptoms
  • Recurrent Depressive Disorder, Current Episode Moderate
  • Recurrent Depressive Disorder, Current Episode Severe Without Psychotic Symptoms

Keywords

  • Randomized Controlled Trial
  • Depression
  • Transcranial Pulsed Electro-Magnetic Fields (T-PEMF)
  • Psychiatry
  • Cognition
  • Sleep
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Meeting the diagnostic criteria for moderate to severe depressive episode without psychotic symptoms according to the International Classification of Diseases and Related Health Problems 10th Revision (ICD-10)(The ICD-10 Classification of Mental and Behavioural Disorders: Diagnostic Criteria for Research 1993).
  • Female participants: Females in the fertile age must deliver a negative pregnancy test, or previously have been sterilized.
  • Female fertile participants: They must use safe methods to be included in the study, and during the whole study.
  • Has given written, to the trial.

Exclusion criteria

Exclusion Criteria:

  • Inability to speak or understand the Danish language.
  • A current high risk of suicide (a score of 2 or more on the HAM-D-17 item 3).
  • A co-morbid substance dependence.
  • Bipolar affective disorder.
  • Psychotic illness.
  • Dementia.
  • Other diagnoses of organic brain disease.
  • The participant has any kind of implant, e.g. pacemakers or cochlear implants.
  • Female participants: Pregnancy
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
117 participants (estimated)

Study arms

  • Experimental
    (A) Patients diagnosed with moderate to severe depression without psychotic symptoms

    In total, 48 patients will be allocated to this arm. (In total, 117 patients will be included in the study. Data for the initial 21 patients included in the study could not be used to assess the antidepressant effect, why an increased number of participants was needed to secure the power for the trial. The technical difficulties have been addressed)

    Device: Treatment with MoodHeadBand (T-PEMF treatment)

  • Sham comparator
    (B) Patients diagnosed with moderate to severe depression without psychotic symptoms

    In total, 48 patients will be allocated to this arm. (In total, 117 patients will be included in the study. Data for the initial 21 patients included in the study could not be used to assess the antidepressant effect, why an increased number of participants was needed to secure the power for the trial. The technical difficulties have been addressed)

    Device: Inactive treatment with MoodHeadBand (Placebo)

Interventions

  • DeviceTreatment with MoodHeadBand (T-PEMF treatment)

    The patients will receive treatment with T-PEMF using a headband containing 20 coils placed symmetrically around the head of the patient. The device delivers 55 Hz magnetic field. Duration of treatment is 30 minutes once a day for 8 weeks.

  • DeviceInactive treatment with MoodHeadBand (Placebo)

    Patients will use an identical device, which does not deliver T-PEMF treatment. The patients will use the headband as the active group for 30 minutes, once a day, for 8 weeks.

06

What researchers measure

Primary outcomes

  1. Inventory of Depressive Symptomatology (Self-Report) (IDS-SR)

    The IDS-SR is a 30-item self-report scale for measuring depressive symptoms, with satisfying psychometric features and good correlations with Hamilton-D17 (HAM-D17).

    Time frame: 8 weeks

Secondary outcomes

  1. Hamilton-D17 (HAM-D17)

    A scale measuring depressive symptoms. Will be applied at baseline and at the end point

    Time frame: 8 weeks

  2. Hamilton-D6 (HAM-D6)

    A scale measuring depressive symptoms. Will be applied at baseline and at the end point.

    Time frame: 8 weeks

  3. Quick Inventory of Depressive Symptomatology

    A quick-version of the IDS questionnaire, that consists of 16 questions. Patients fill this assesment on a weekly basis during the study.

    Time frame: 8 weeks

  4. WHO-5

    This Well-Being Index consists of five items that are scored on a frequency response scale from "none of the time" (0) to "all of the time" (5).

    Time frame: 8 weeks

  5. Facial Expression and Recognition Test (FERT)

    A test that assesses the patients recognition of - and attention to facial expressions as a part of the cognitive test battery that explores the patients "hot" cognition.

    Time frame: 8 weeks

  6. Emotional Categorization and Memory Test (ECMT)

    A test that assesses the patient' self-referential memory with emotion laded words as a part of the cognitive test battery that explores the patients' "hot" cognition.

    Time frame: 8 weeks

  7. Screening of cognitive impairment in Psychiatry (SCIP)

    A screening tool used to assess cognitive performance in psychiatric patients. The test includes List learning, delayed list learning, verbal fluency, visuomotor tracking tests. Explores the patients' "cold" cognitive mechanisms.

    Time frame: 8 weeks

  8. Trail Making Test B (TMT-B)

    A test that assesses the patients' visual attention and ability to switch tasks. Explores the patients' "cold" cognitive mechanisms.

    Time frame: 8 weeks

  9. Sleep diary

    The diary explores the patients sleep pattern and quality of sleep.

    Time frame: 8 weeks

  10. Udvalget for Kliniske Undersøgelser scale (UKU-24)

    Side effects are assessed by the UKU-24 scale, including free text comments. Side effects will be assesed at week 1, 2, 4, 6 and at the end point.

    Time frame: 8 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Brandborg Sorensen N, Haahr U, Larsen MP, Hansen J, Nyholm S, Videbech P, Bohr T, Miskowiak KW, Martiny K, Jorgensen MB. Active versus sham transcranial pulsed electromagnetic field headband treatment for major depression: protocol for a double-blinded randomised trial. BMJ Open. 2025 Oct 20;15(10):e104474. doi: 10.1136/bmjopen-2025-104474. PubMed 41120157 ↗

Individual participant data

Plan to share: No — It is not possible to share individual participant data due to GDPR. Anonymised data after publishing might be available per request.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2024 (actual). Primary completion is estimated for Aug 2026, 26 months after the start.

Of 261 non-industry interventional studies with no phase under Depressive Disorder, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 45. This study's planned 26 months is below that.

Counting every sponsor, half of 276 studies reached it within 29 months; a quarter within 15 and three quarters within 45.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 15, 2023
First posted
Aug 22, 2023
StartActual
Jun 17, 2024
Primary completionEst.
Aug 30, 2026
CompletionEst.
Aug 30, 2026
Last update
Aug 26, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 26, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06005103
Lead sponsor
Mental Health Centre Copenhagen, Bispebjerg and Frederiksberg Hospital
Collaborators
Innovation Fund Denmark, Danish Medical Association, Doctor Gerhard Linds scholarship, MoodHeadBand Aps
Responsible party
Martin Balslev Jørgensen (Professor, dr. med., Mental Health Centre Copenhagen, Bispebjerg and Frederiksberg Hospital) — Principal investigator
First posted
Aug 22, 2023
Start date
Jun 17, 2024
Primary completion
Aug 30, 2026 (estimated)
Completion
Aug 30, 2026 (estimated)
Last update
Aug 26, 2025

Study contacts

Martin B. Jørgensen, MD DMSc
Contact
Martin.Balslev.Joergensen@regionh.dk
23328669 ext. +45
Nana B Sørensen, MD
Contact
nana.brandborg.soerensen@regionh.dk
26356751 ext. +45
Martin B. Jørgensen, MD MSc
principal investigator · Psychiatric Center Copenhagen

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion